Asymmetric dimethylarginine: a risk indicator or pathogenic factor?

Asymmetric dimethylarginine: a risk indicator or pathogenic factor?

Asymmetric Dimethylarginine (adma): a Mediator of Endothelial Dysfunction and a Novel Cardiovascular Risk Factor

Asymmetric dimethylarginine (ADMA) is involved in the pathogenesis of hypertension and atherosclerosis by inhibiting the generation of nitric oxide, an endogenous vasculoprotective molecule. Determination of ADMA helps to predict a patient`s probability of experiencing death or cardiovascular disease. A novel competitive ADMA-ELISA that has recently been developed and validated by us is a usefu...

Role in Hypercholesterolemia Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction

Rainer H. Böger, Stefanie M. Bode-Böger, Andrzej Szuba, Philip S. Tsao, Jason R. Chan, : Its Role in Hypercholesterolemia Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 1998 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Da...

Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.

BACKGROUND Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide (NO) synthase. Because endothelial NO elaboration is impaired in hypercholesterolemia, we investigated whether plasma concentrations of ADMA are elevated in young, clinically asymptomatic hypercholesterolemic adults. We further studied whether such elevation of ADMA levels was correlated with im...

The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.

There is abundant evidence that the endothelium plays a crucial role in the maintenance of vascular tone and structure. One of the major endothelium-derived vasoactive mediators is nitric oxide (NO). Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthase. ADMA inhibits vascular NO production at concentrations found in pathophysiological conditions (i.e., 3-15 micromol/l); ...